准小型的与ubiquitin相关的修饰剂特异蛋白酶2减弱了瘤的进展,并协调瘤免疫微环境在扩散的大B细胞淋巴瘤中
Xue Sheng1,2, Dongmei Wang1,2, Shuying Li1,2
1Department of Hematology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
British journal of haematology
|October 1, 2025
概括
SUMO特异性蛋白酶2 (SENP2) 在扩散性大B细胞淋巴瘤 (DLBCL) 中过度表达,促进癌症生长. 针对SENP2可能为DLBCL患者提供新的治疗策略.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是一种具有有限治疗选择的侵袭性癌症.
- 新的治疗目标对于改善患者的治疗结果至关重要.
- 在DLBCL病变发生过程中,SUMO特异蛋白酶2 (SENP2) 的作用在很大程度上是未知的.
研究的目的:
- 调查SENP2在DLBCL中的作用.
- 评估SENP2作为DLBCL的预后生物标志物和治疗标.
主要方法:
- 在DLBCL患者样本中分析SENP2表达.
- 构建一个结合SENP2.2的预后名ogram.
- 在体外和体内研究评估SENP2在DLBCL细胞增殖中的作用.
- RNA测序和免疫细胞分析.
- 针对SENP2.2的FDA批准的药物的虚拟查.
主要成果:
- 在DLBCL中,SENP2显著过度表达,与预后不佳相关.
- SENP2促进DLBCL细胞的增殖.
- 在SENP2中,SENP2淘汰会降低髓质衍生抑制细胞,并增强CD8+T细胞活性.
- 一个整合SENP2表达式的nomogram显示了强大的预测能力.
结论:
- SENP2是一种DLBCL的新预后生物标志物.
- 准SENP2为DLBCL提供了一个有前途的治疗策略.
- 在DLBCL中,SENP2会影响瘤免疫微环境.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
The Intrinsic Apoptotic Pathway
8.3K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.3K
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Receptor Downregulation in MVBs
2.8K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.8K


